Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson's Disease

被引:50
|
作者
Lieu, Christopher A. [1 ]
Chinta, Shankar J. [1 ]
Rane, Anand [1 ]
Andersen, Julie K. [1 ]
机构
[1] Buck Inst Res Aging, Novato, CA USA
来源
PLOS ONE | 2013年 / 8卷 / 01期
关键词
MAO-B; 3-NITROPROPIONIC ACID; BRAIN ASTROCYTES; KNOCKOUT MICE; PC12; CELLS; MPTP; DEFICIENT; NEURONS; NEUROTOXICITY; DEGENERATION;
D O I
10.1371/journal.pone.0054200
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have previously shown that increases in astrocytic monoamine oxidase-B (MAO-B) expression, mimicking that which occurs with aging and in neurodegenerative disease, in a doxycycline (dox)-inducible transgenic mouse model evokes neuropathological similarities to what is observed in the human parkinsonian brain. Additional behavioral and neuropathological studies could provide further validation for its usage as a model for Parkinson's disease (PD). In the present study, we utilized a battery of behavioral tests to evaluate age-related phenotype in this model. In the open field test, we found that dox-induction impaired motor ability with decreases in movement and ambulatory function as well as diminished stereotypical, repetitive movement episodes in both young and old mice. Older mice also showed decreased motor performance in the pole test when compared to younger mice. Furthermore, dox-induced older mice displayed severe hindlimb clasping and the most significant loss of dopamine (DA) in the striatum when compared to young and non-induced animals. Additionally, increased MAO-B activity significantly correlated with decreased expression of striatal DA. The results of our study further confirms that the dox-inducible astrocytic MAO-B transgenic mouse displays similar age-related behavioral and neuropathological features to other models of PD, and could serve as a useful tool to study PD pathophysiology and for the evaluation of therapeutic interventions.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease
    Kang, Seong Su
    Ahn, Eun Hee
    Zhang, Zhentao
    Liu, Xia
    Manfredsson, Fredric P.
    Sandoval, Ivette M.
    Dhakal, Susov
    Iuvone, P. Michael
    Cao, Xuebing
    Ye, Keqiang
    EMBO JOURNAL, 2018, 37 (12)
  • [2] Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease
    Robakis, Daphne
    Fahn, Stanley
    CNS DRUGS, 2015, 29 (06) : 433 - 441
  • [3] Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson's Disease
    Husain, Maroof
    Shukla, Rakesh
    Dikshit, Madhu
    Maheshwari, Pradeep K.
    Nag, Devika
    Srimal, Rikhab C.
    Seth, Prahlad K.
    Khanna, Vinay K.
    NEUROCHEMICAL RESEARCH, 2009, 34 (08) : 1427 - 1432
  • [4] Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice
    Rajeswari A.
    Sabesan M.
    Inflammopharmacology, 2008, 16 (2) : 96 - 99
  • [5] The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
    Quinn, L. P.
    Crook, B.
    Hows, M. E.
    Vidgeon-Hart, M.
    Chapman, H.
    Upton, N.
    Medhurst, A. D.
    Virley, D. J.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (01) : 226 - 233
  • [6] Monoamine Oxidase B Inhibitors in Parkinson's Disease
    Dezsi, Livia
    Vecsei, Lzszlo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 425 - 439
  • [7] Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease
    Park, Hye Ri
    Kim, Jiyoon
    Kim, Taekeun
    Jo, Seonmi
    Yeom, Miyoung
    Moon, Bongjin
    Choo, Il Han
    Lee, Jaeick
    Lim, Eun Jeong
    Park, Ki Duk
    Min, Sun-Joon
    Nam, Ghilsoo
    Keum, Gyochang
    Lee, C. Justin
    Choo, Hyunah
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (17) : 5480 - 5487
  • [8] Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging
    Bar-Am, Orit
    Amit, Tamar
    Kupershmidt, Lana
    Aluf, Yuval
    Mechlovich, Danit
    Kabha, Hoda
    Danovitch, Lena
    Zurawski, Vincent R.
    Youdim, Moussa B. H.
    Weinreb, Orly
    NEUROBIOLOGY OF AGING, 2015, 36 (03) : 1529 - 1542
  • [9] Behavioral phenotyping of the MPTP mouse model of Parkinson's disease
    Sedelis, M
    Schwarting, RKW
    Huston, JP
    BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) : 109 - 125
  • [10] Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients
    Zellner, Maria
    Baureder, Michael
    Rappold, Eduard
    Bugert, Peter
    Kotzailias, Nicole
    Babeluk, Rita
    Baumgartner, Roland
    Attems, Johannes
    Gerner, Christopher
    Jellinger, Kurt
    Roth, Erich
    Oehler, Rudolf
    Umlauf, Ellen
    JOURNAL OF PROTEOMICS, 2012, 75 (07) : 2080 - 2092